MX364396B - Poli(beta-amino esteres) modificados para suministro de farmaco. - Google Patents

Poli(beta-amino esteres) modificados para suministro de farmaco.

Info

Publication number
MX364396B
MX364396B MX2015011393A MX2015011393A MX364396B MX 364396 B MX364396 B MX 364396B MX 2015011393 A MX2015011393 A MX 2015011393A MX 2015011393 A MX2015011393 A MX 2015011393A MX 364396 B MX364396 B MX 364396B
Authority
MX
Mexico
Prior art keywords
polymers
beta
drug delivery
amino ester
modified poly
Prior art date
Application number
MX2015011393A
Other languages
English (en)
Other versions
MX2015011393A (es
Inventor
Borrós Gómez Salvador
Ramos Pérez Victor
Dosta Pons Pere
Verónica Segovia Ramos Nathaly
Original Assignee
Institut Quim De Sarria Cets Fundacio Privada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Quim De Sarria Cets Fundacio Privada filed Critical Institut Quim De Sarria Cets Fundacio Privada
Publication of MX2015011393A publication Critical patent/MX2015011393A/es
Publication of MX364396B publication Critical patent/MX364396B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Abstract

La presente invención se refiere a polímeros que son polo (beta-amino ésteres) (PBAEs) modificados con al menos un oligopéptido. Los polímeros pueden ser usados en cualquier campo donde los polímeros han encontrado ser útiles, que incluyen en campos médicos, particularmente en suministro de fármaco. Los polímeros son particularmente útiles en el suministro de un polinucleótido tal como ADN, ARN y siARN, una molécula pequeña o una proteína. También se describen composiciones que comprenden tales polímeros y un agente activo, métodos para encapsular un agente en una matriz de tales polímeros, y tales polímeros y composiciones para uso en medicina.
MX2015011393A 2013-03-08 2014-03-10 Poli(beta-amino esteres) modificados para suministro de farmaco. MX364396B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1304245.2A GB201304245D0 (en) 2013-03-08 2013-03-08 Chemical compounds
PCT/IB2014/059594 WO2014136100A1 (en) 2013-03-08 2014-03-10 Modified poly(beta-amino ester)s for drug delivery

Publications (2)

Publication Number Publication Date
MX2015011393A MX2015011393A (es) 2016-06-06
MX364396B true MX364396B (es) 2019-04-25

Family

ID=48189627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011393A MX364396B (es) 2013-03-08 2014-03-10 Poli(beta-amino esteres) modificados para suministro de farmaco.

Country Status (17)

Country Link
US (2) US20160038598A1 (es)
EP (1) EP2964244B1 (es)
JP (1) JP6473421B2 (es)
KR (1) KR102191195B1 (es)
CN (1) CN105324120B (es)
AR (1) AR095081A1 (es)
AU (1) AU2014224219B2 (es)
BR (1) BR112015021709B8 (es)
CA (1) CA2903663C (es)
DK (1) DK2964244T3 (es)
ES (1) ES2781965T3 (es)
GB (1) GB201304245D0 (es)
MX (1) MX364396B (es)
PL (1) PL2964244T3 (es)
RU (1) RU2015142677A (es)
TW (1) TW201446269A (es)
WO (1) WO2014136100A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201801654RA (en) 2014-05-28 2018-04-27 Childrens Hospital Med Ct Methods and systems for converting precursor cells into gastric tissues through directed differentiation
EP3207123A1 (en) 2014-10-17 2017-08-23 Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
GB201501025D0 (en) * 2015-01-21 2015-03-04 Sagetis Biotech Sl Chemical compounds
CA3009317A1 (en) * 2015-12-23 2017-06-29 Viking Scientific, Inc. Hydrogel prodrug for treatment
CN105535994B (zh) * 2015-12-25 2018-01-19 华中科技大学同济医学院附属同济医院 一种治疗hpv感染的纳米粒制剂及其制备方法
WO2017192997A1 (en) 2016-05-05 2017-11-09 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
SG10202105768WA (en) 2016-12-05 2021-06-29 Childrens Hospital Med Ct Colonic organoids and methods of making and using same
CN106727313B (zh) * 2017-01-06 2020-04-10 国家纳米科学中心 一种载药聚合物纳米胶束及其制备方法和应用
GB201708203D0 (en) * 2017-05-22 2017-07-05 Sagetis Biotech Sl Chemical compounds
US11464860B2 (en) 2017-10-27 2022-10-11 Massachusetts Institute Of Technology Poly (beta-amino esters) and uses thereof
EP3703760A1 (en) 2017-11-03 2020-09-09 Massachusetts Institute Of Technology Gene delivery carrier
AU2019213290A1 (en) * 2018-01-17 2020-08-06 Ixaka France SAS Polymer-encapsulated viral vectors for genetic therapy
US20220228211A1 (en) * 2019-05-31 2022-07-21 Children's Hospital Medical Center Polymer based cellular labeling, barcoding and assembly
EP4058585A1 (en) 2019-11-15 2022-09-21 Ixaka France Polymer-encapsulated viral vectors for in vivo genetic therapy
WO2021255262A1 (en) 2020-06-19 2021-12-23 Sylentis Sau siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
EP4247895A1 (en) * 2020-11-19 2023-09-27 Encapsys, LLC Poly acrylate and poly(beta-ester) capsules with enhanced degradability
EP4015634A1 (en) 2020-12-15 2022-06-22 Sylentis, S.A.U. Sirna and compositions for prophylactic and therapeutic treatment of virus diseases
WO2023006651A1 (en) * 2021-07-26 2023-02-02 Institut Quimic De Sarria Cets Fundacio Privada Covalently coated adeno-associated virus vector for its use in gene therapy
EP4166594A1 (en) 2021-10-14 2023-04-19 Institut Químic de Sarrià CETS Fundació Privada Zwitterionic functionalized poly(beta-aminoester) polymers and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1313873A (zh) * 1998-07-13 2001-09-19 表达遗传学公司 作为可溶性,生物可降解基因送递载体的聚－l－赖氨酸的聚酯类似物
US7427394B2 (en) * 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
PL1796650T3 (pl) * 2004-09-14 2009-06-30 Nanodel Tech Gmbh Nanocząstki zawierające dostarczające podłoże
EP2046266A4 (en) 2006-07-21 2009-11-04 Massachusetts Inst Technology ENDMODICIFIED POLY (BETA AMINO ESTER) AND ITS USE
US9717694B2 (en) * 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
GB0913442D0 (en) * 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
WO2013056113A1 (en) * 2011-10-13 2013-04-18 The Johns Hopkins University Nanocomposites of gold and polymers

Also Published As

Publication number Publication date
CA2903663A1 (en) 2014-09-12
EP2964244A1 (en) 2016-01-13
JP6473421B2 (ja) 2019-02-20
GB201304245D0 (en) 2013-04-24
EP2964244B1 (en) 2020-01-08
CN105324120B (zh) 2021-04-02
BR112015021709A2 (pt) 2017-07-18
BR112015021709B8 (pt) 2022-04-05
TW201446269A (zh) 2014-12-16
US20180250410A1 (en) 2018-09-06
WO2014136100A1 (en) 2014-09-12
KR102191195B1 (ko) 2020-12-16
CN105324120A (zh) 2016-02-10
DK2964244T3 (da) 2020-04-06
BR112015021709B1 (pt) 2022-03-03
RU2015142677A (ru) 2017-04-13
JP2016511316A (ja) 2016-04-14
CA2903663C (en) 2022-08-30
MX2015011393A (es) 2016-06-06
US20160038598A1 (en) 2016-02-11
AR095081A1 (es) 2015-09-16
PL2964244T3 (pl) 2020-08-24
AU2014224219A1 (en) 2015-09-24
KR20150135334A (ko) 2015-12-02
ES2781965T3 (es) 2020-09-09
AU2014224219B2 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
MX2015011393A (es) Poli(beta-amino esteres) modificados para suministro de farmaco.
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
CA2863964C (en) Compartmentalized method of nucleic acid delivery and compositions and uses thereof
BR112015015319A2 (pt) composições de nanopartícula de albumina e paclitaxel
MX2018001511A (es) Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos.
MX2021008464A (es) Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
SG10201902915VA (en) Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
WO2015095624A3 (en) Drug mixing and delivery system and method
MX2013003892A (es) Composicion farmaceutica liquida para el suministro de ingredientes activos.
MD20160079A2 (ro) Sistem de livrare a medicamentului
MX2015008286A (es) Composiciones multipolimericas para liberación transdermica de farmaco.
WO2013028942A8 (en) Targeting microbubbles
IN2015KN00005A (es)
PH12018500449A1 (en) Polymeric bile acid nanocompositions targeting the pancreas and colon
MX2015012060A (es) Forma de dosificacion solida de disuasivo del abuso para liberacion inmediata con marca funcional.
WO2015031771A3 (en) Administration of kynurenine depleting enzymes for tumor therapy
AR105223A1 (es) Compuestos químicos
MX2018001499A (es) Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.
MX2014014717A (es) Formulacion farmaceutica.
MX2015013187A (es) Composiciones de anfetamina transdermica estable y metodos de fabricacion.
GB2528421A (en) Methods and processes for application of drug delivery polymeric coatings
MX2013013691A (es) Composicion de liberacion sostenida que contiene peptidos como ingredientes activos.
CL2012003209A1 (es) Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico.
PE20160850A1 (es) Sistema multiparticulado para administrar drogas
PH12017501563A1 (en) Oligomeric/polymeric silicone fluids for use in transdermal drug delivery systems

Legal Events

Date Code Title Description
FG Grant or registration